Ohcanbohtosat - "BRCA mutation"

A Clinical Trial to Increase the Identification, Genetic Counseling Referral and Genetic Testing of Women at risk for Hereditary Breast and/or Ovarian Cancer Dahkki Ceceilia Bellcross, Christine Stanislaw, April Hermstad, Christine Tallo, Chelsea Leonard

Connect to this object online.

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers Dahkki Tingting Du, Zhihui Zhang, Jie Zhou, Li Sheng, Haiping Yao, Ming Ji, Bailing Xu, Xiaoguang Chen, Xiaoguang Chen

Connect to this object online.

Is there an epigenetic component underlying the resistance of triple-negative breast cancers to PARP inhibitors? Dahkki Amanda eLovato, Lawrence ePanasci, Michael eWitcher

Connect to this object online.

Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia Dahkki Xing Bian, Wenli Liu, Kaijin Yang, Chuanbo Sun

Connect to this object online.

Exceptional response to lurbinectedin and irinotecan in -mutated platinum-resistant ovarian cancer patient: a case report Dahkki Laura Cortesi, Marta Venturelli, Elena Barbieri, Cinzia Baldessari, Camilla Bardasi, Emanuele Coccia, Federica Baglio, Margherita Rimini, Stefano Greco, Martina Napolitano, Stefania Pipitone, Massimo Dominici

Connect to this object online.

A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report Dahkki Deqiang Wang, Ruting Guan, Qing Tao, Sisi Liu, Man Yu, Xiaoqin Li

Connect to this object online.

BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy Dahkki Salar Farokhi Boroujeni, Galaxia Rodriguez, Kristianne Galpin, Edward Yakubovich, Humaira Murshed, Dalia Ibrahim, Sara Asif, Barbara C. Vanderhyden

Connect to this object online.

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer Dahkki Colombo I, Lheureux S, Oza AM

Connect to this object online.

Resistance to PARP Inhibitors After First-Line Platinum-Based Chemotherapy in a Patient with Advanced Ovarian Cancer with a Pathogenic Somatic BRCA1 Mutation Dahkki Zhong L, Yin R, Song L

Connect to this object online.

BRCA1/2 mutations and survival of high-grade endometrioid endometrial cancer Dahkki Yibo Dai, Jingyuan Wang, Luyang Zhao, Zhiqi Wang

Connect to this object online.

Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer - International considerations amongst upper m... Dahkki Jeffrey C.H. Goh, Charlie Gourley, David S P Tan, Angélica Nogueira-Rodrigues, Hesham Elghazaly, Marc Edy Pierre, Gonzalo Giornelli, Byoung-Gie Kim, Flavia Morales-Vasquez, Alexandra Tyulyandina

Connect to this object online.

Ovarian cancer arising from the proximal fallopian tube in a patient with a BRCA2 mutation Dahkki Nora Badiner, Corbyn M. Nchako, Lucy Ma, Melissa K. Frey

Connect to this object online.

Profile of olaparib in the treatment of advanced ovarian cancer Dahkki Chase DM, Patel S, Shields K

Connect to this object online.

Could recurrent aphthous stomatitis be linked to cancer development? Dahkki Emily Norton

Connect to this object online.

Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer Dahkki Xu Huang, Xu Huang, Xiao-Yu Li, Xiao-Yu Li, Wu-Lin Shan, Yao Chen, Qi Zhu, Bai-Rong Xia

Connect to this object online.

Level of tumor-infiltrating lymphocytes and PD status as potential prognostic markers of survival and therapy effectiveness in triple-negative breast cancer Dahkki A. F. Nasretdinov, N. I. Sultanbaeva, Sh. I. Musin, A. V. Pushkarev, K. V. Menshikov, V. A. Pushkarev, A. V. Sultanbaev

Connect to this object online.

Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series Dahkki Jing Ni, Rui Zhou, Xianzhong Cheng, Xia Xu, Wenwen Guo, Xiaoxiang Chen

Connect to this object online.

Modern possibilities for the correction of menopausal symptoms in patients with breast cancer, depending on the molecular biological characteristics of the tumor (literature review... Dahkki I. V. Vysotskaya, E. A. Kim, M. V. Geletko, F. E. Misrikhanova, V. Yu. Kirsanov

Connect to this object online.

Defective DNA repair mechanisms in prostate cancer: impact of olaparib Dahkki De Felice F, Tombolini V, Marampon F, Musella A, Marchetti C

Connect to this object online.

Investigating the Effects of Olaparib on the Susceptibility of Glioblastoma Multiforme Tumour Cells to Natural Killer Cell-Mediated Responses Dahkki Jennifer Moran, Eimear Mylod, Laura E. Kane, Caroline Marion, Emily Keenan, Marianna Mekhaeil, Joanne Lysaght, Kumlesh K. Dev, Jacintha O'Sullivan, Melissa J. Conroy

Connect to this object online.